Compare Canadian National Railway Co. (CNI) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian National Railway Co. vs Ginkgo Bioworks Holdings Inc — how do they compare? Canadian National Railway Co. trades at $126.3 (market cap $76.28B), while Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M). The key difference: Canadian National Railway Co. is far larger — about 150.8× Ginkgo Bioworks Holdings Inc's market cap, and Canadian National Railway Co. pays a 2.06% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| CNI | DNA | |
|---|---|---|
Market Cap | $76.28B | $505.73M |
Sector | Industrials | Health |
52-Week High | $130.58 | $16.14 |
52-Week Low | $90.91 | $5.48 |
Enterprise Value | $92.31B | $607.68M |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CNI trades at $126.29, up 0.91% on the day, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.50, and raised its full-year guidance, driven by record grain volumes and operational efficiency. Financials show solid profitability with a net income margin of 26.92% and ROE of 22.02%, though valuation ratios like P/E of 22.62 appear elevated.
The outlook is positive due to robust operational performance and raised guidance, but risks include stretched valuation, economic sensitivity, and competitive pressures. Analyst consensus is a Buy with a $152.38 price target, implying potential upside, though recent downgrades highlight valuation concerns.
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
